
Investing.com —— 葛兰素史克(GSK Plc)获得美国食品药品监督管理局(FDA)批准,其肺癌新药neladalkib可上市销售,商品名为Nelkarmi。此次获批为这家英国药企收购生物技术公司Nuvalent提供了进一步验证。
Investing.com -- GSK Plc received US Food and Drug Administration approval for its lung cancer drug neladalkib, which will be marketed under the brand name Nelkarmi. The approval adds validation to the British drugmaker's acquisition of biotechnology company Nuvalent.
FDA批准Nelkarmi用于治疗由ALK基因突变驱动的一种非小细胞肺癌,该突变会导致异常细胞生长。该药获批用于经早期ALK靶向药物治疗后疾病仍有进展的局部晚期或转移性患者。
The FDA cleared Nelkarmi for a form of non-small cell lung cancer driven by a mutation in the ALK gene, which causes abnormal cell growth. The drug is approved for patients with locally advanced or metastatic disease that has progressed despite treatment with earlier generation drugs targeting ALK.
立即开启InvestingPro,获取市场利好头条即时提醒 —— 现享55%优惠。
Get instant alerts on market-moving headlines with InvestingPro — now 55% off.
葛兰素史克通过今年早些时候斥资106亿美元收购Nuvalent获得了该药物权益。同一笔收购还为葛兰素史克带来了另一种名为Jideytro的药物,后者已于7月获得美国批准。
GSK acquired rights to the medication through its $10.6 billion purchase of Nuvalent earlier this year. The same acquisition also brought GSK another drug called Jideytro, which received US approval in July.





FDA在该药于早期临床试验中显示出有意义的抗癌活性后,授予Nelkarmi加速批准。该药物的副作用与现有ALK靶向药物相似,但采用了更新的方法。一项旨在确定其完整获益的晚期研究仍在进行中。
The FDA granted Nelkarmi accelerated approval after the drug showed meaningful anti-cancer activity in an earlier stage clinical trial. The medication has side effects similar to existing drugs that target ALK but uses a newer approach. A late-stage study to determine its full benefits remains ongoing.
接受彭博调查的分析师估计,Nelkarmi到2032年销售额可能达到约10亿美元。杰富瑞分析师Michael Leuchten在获批前致客户的报告中表示,该药物在2030年及以后具有“显著的上行潜力”。
Analysts surveyed by Bloomberg estimate Nelkarmi could generate approximately $1 billion in sales in 2032. Jefferies analyst Michael Leuchten said the medicine has "meaningful upside potential" into 2030 and beyond in a note to clients before the approval.
收购Nuvalent是葛兰素史克首席执行官Luke Miels扩大肿瘤学产品组合战略的核心部分。Miels面临压力,需强化投资者认为落后于竞争对手的药物管线。
The Nuvalent acquisition formed a central part of GSK's strategy to expand its oncology portfolio under Chief Executive Officer Luke Miels. Miels faces pressure to strengthen a pipeline that investors view as lagging behind competitors.
葛兰素史克肿瘤研发负责人Hesham Abdullah表示,公司正在打造肺癌药物系列,并开发治疗血液癌和胃肠道癌症等其他疾病的药物。
Hesham Abdullah, GSK's head of oncology R&D, said the company is building a lung cancer drug franchise and developing other medicines for conditions including blood and gastrointestinal cancers.